CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers
CERo Therapeutics activated Fred Hutch Cancer Center in Seattle as a new site for the Phase 1/1b CERTAIN-T trial of CER-1236 in hematologic malignancies. Fred Hutch is the only NCI-designated cancer center in Washington state, with Dr. Jacob Appelbaum serving as principal investigator at the site. The company reiterated interim findings from six patients across the first two cohorts — no DLTs, CRS, ICANS or treatment-related serious adverse events — while noting no definitive efficacy conclusions can be drawn.
Key figures
- Drug Name
- CER-1236
- Phase Of Trial
- Phase 1/1b
- Dlt window days
- 28
- Patients treated to date
- 6
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.